Dexamethasone sodium phosphate
Phase 3Terminated 0 watching 0 views this week๐ Rising
69
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Ataxia Telangiectasia
Conditions
Ataxia Telangiectasia
Trial Timeline
Dec 11, 2024 โ Jan 30, 2026
NCT ID
NCT06664853About Dexamethasone sodium phosphate
Dexamethasone sodium phosphate is a phase 3 stage product being developed by Quince Therapeutics for Ataxia Telangiectasia. The current trial status is terminated. This product is registered under clinical trial identifier NCT06664853. Target conditions include Ataxia Telangiectasia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06664853 | Phase 3 | Terminated |
| NCT06193200 | Phase 3 | Completed |
Competing Products
20 competing products in Ataxia Telangiectasia